Feasibility of the Gastrografin Challenge for Adhesive Small Bowel Obstruction
10.17479/jacs.2021.11.2.58
- Author:
Ki-Sang JUNG
1
;
Kyoung-Jin CHOI
;
Kyoung-Won YOON
;
Kee-Sang YOO
;
Eun-Mi GIL
;
Chi-Min PARK
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:
Journal of Acute Care Surgery
2021;11(2):58-63
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This retrospective study investigated the feasibility, diagnostic, and therapeutic advantages of the gastrografin challenge on patients with adhesive small bowel obstruction (ASBO).
Methods:There were 125 patients reviewed who were admitted to the Department of General Surgery at a single institution (September 2018 to August 2019) with a diagnosis related to ASBO. The study population included 100 patients (114 cases) who had received initial conservative management. Patient characteristics and operation rates were compared between the gastrografin challenge success group and failure group, and operation rates and length of hospital stay were compared between the gastrografin challenge group and “non-challenge” group.
Results:During the study period, 21 patients with ASBO underwent the gastrografin challenge. The challenge was successful in 17 patients where the bowel obstruction was resolved without the need for surgery. Among patients who failed the challenge, 2 patients underwent adhesiolysis and 2 patients were able to progress their diet avoiding surgery. In patients who underwent surgery (n = 2), the length of hospital stay was significantly shorter in the gastrografin challenge group compared with the “non-challenge” group sub analysis (n = 13 cases; 10.5 vs. 20 days, p = 0.038), indicating that the gastrografin challenge assisted rapid decision-making for surgery. No adverse events were reported for the 21 gastrografin challenges.
Conclusion:In patients with ASBO, the gastrografin challenge is an accurate, safe method to determine the need for surgery. In addition, the gastrografin challenge may reduce the length of stay in patients who required surgery for ASBO resolution.
